Nitric Oxide Metabolites, Leukocyte Activation Markers and Oxidative Status in Dialyzed Subjects

被引:16
作者
Caimi, G. [1 ]
Carollo, C. [1 ]
Montana, M. [1 ]
Iatrino, R. [1 ]
Bondi, B. [1 ]
Lo Presti, R. [1 ]
机构
[1] Univ Palermo, Dipartimento Med Interna Malattie Cardiovasc & Ne, IT-90127 Palermo, Italy
关键词
Hemodialysis; Oxidative status; Nitric oxide; Elastase; Myeloperoxidase; CHRONIC-RENAL-FAILURE; CHRONIC KIDNEY-DISEASE; MAINTENANCE HEMODIALYSIS-PATIENTS; CARDIOVASCULAR-DISEASE; SERUM MALONDIALDEHYDE; ANTIOXIDANT CAPACITY; NEUTROPHIL ELASTASE; LIPID-PEROXIDATION; PLASMA-LEVELS; VITAMIN-E;
D O I
10.1159/000193218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Our purpose was to evaluate, in a group of 42 end-stage renal disease patients who regularly undergo hemodialysis, some indexes of leukocyte activation, nitric oxide metabolites (NOx) and other parameters that reflect the oxidative stress before and after a standard hemodialysis session. Methods: Elastase and myeloperoxidase (MPO) were determined by means of ELISA. The NO production was evaluated by a micromethod which measures the concentration of NOx. The oxidation of polyunsaturated fatty acids was evaluated in plasma by detection of thiobarbituric acid-reactive substances (TBARS). Total antioxidant status (TAS) was obtained using spectrophotometry. Results: At baseline, we observed an increase of elastase, NOx, TBARS and TAS, without any variation of MPO. After the dialysis session, we found an increase in elastase and MPO, a decrease in NOx and TAS and no variation in TBARS. No modification occurred after subdividing the patients in two subgroups. Conclusions: Our data confirm the involvement of leukocytes and oxidative stress in hemodialysis patients. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:194 / 198
页数:5
相关论文
共 46 条
[1]   Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis [J].
Boaz, M ;
Matas, Z ;
Biro, A ;
Katzir, Z ;
Green, M ;
Fainaru, M ;
Smetana, S .
KIDNEY INTERNATIONAL, 1999, 56 (03) :1078-1083
[2]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[3]   Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients [J].
Boaz, M ;
Matas, Z ;
Biro, A ;
Katzir, Z ;
Green, M ;
Fainaru, M ;
Smetana, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (03) :438-444
[4]   Causes of death after renal transplantation [J].
Briggs, JD .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (08) :1545-1549
[5]   Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance [J].
Chu, Pei-Lun ;
Chiu, Yen-Ling ;
Lin, Jou-Wei ;
Chen, Shih-I ;
Wu, Kwan-Dun .
BLOOD PURIFICATION, 2008, 26 (02) :213-220
[6]   Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: An Italian multicenter study [J].
Cruz, D. N. ;
De Cal, M. ;
Garzotto, F. ;
Brendolan, A. ;
Nalesso, F. ;
Corradi, V. ;
Ronco, C. .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (06) :545-552
[7]  
Cruz DN, 2008, CONTRIB NEPHROL, V161, P89, DOI 10.1159/000130413
[8]   Is chronic kidney disease a cardiovascular disease risk factor? [J].
Culleton, BF ;
Hemmelgarn, BR .
SEMINARS IN DIALYSIS, 2003, 16 (02) :95-100
[9]   Impaired plasma nitric oxide availability and extracellular superoxide dismutase activity in healthy humans with advancing age [J].
Di Massimo, C ;
Scarpelli, P ;
Di Lorenzo, N ;
Caimi, G ;
di Orio, F ;
Ciancarelli, MGT .
LIFE SCIENCES, 2006, 78 (11) :1163-1167
[10]   Neutrophil elastase in human atherosclerotic plaques - Production by macrophages [J].
Dollery, CM ;
Owen, CA ;
Sukhova, GK ;
Krettek, A ;
Shapiro, SD ;
Libby, P .
CIRCULATION, 2003, 107 (22) :2829-2836